© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
Astellas, Pfizer and Triton. Dr. Matt T. Rosenberg has
been a speaker and consultant for Astellas, Easai,
Ferring, Forest, Horizon, Ortho-McNeil, Lilly, Pfizer
and Bayer. Dr. Martin Miner has been a consultant
for Abbvie and Endo. He has also done research for
Forest.
References
1. Tomson C, Porter T. Asymptomatic microscopic or dipstick
haematuria in adults: which investigations for which patients?
A review of the evidence.
BJU Int
2002;90(3):185-198.
2. Moyer VA, U.S. Preventive Services Task Force. Screening
for prostate cancer: U.S. Preventive Services Task Force
recommendation statement.
Ann Int Med
2012;157(2):120-134.
3. Izawa JI, Klotz L, Siemens DR et al. Prostate cancer screening:
Canadian Guidelines 2011.
Can Urol Assoc J
2011;5(4):235-240.
4. Carter HB, Albertsen PC, Barry MJ et al. Early detection of
prostate cancer. AUA guideline.
J Urol
2013;190(2):419-426
5. Heidenreich A, Abrahamsson PA, Artibani W et al. Early
detection of prostate cancer: European Association of Urology
recommendation.
Eur Urol
2013;64(3):347-354.
6. Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung,
Colorectal andOvarian Cancer Screening Trial Project Team. The
Prostate, Lung, Colorectal andOvarian (PLCO) Cancer Screening
Trial of the National Cancer Institute: history, organization and
status.
Control Clin Trials
2000;21(6 Suppl):251S-272S.
7. Gomella LG, Liu XS, Trabulsi EJ et al. Screening for prostate
cancer: the current evidence and guidelines controversy.
Can J
Urol
2011;18(5):5875-5883.
8. Schroder FH, Hugosson J, Roobol MJ et al. Screening and
prostate-cancer mortality in a randomized European study.
N Engl J Med
2009;360(13):1320-1328.
9. Hugosson J, Carlsson S, Aus G et al. Mortality results from
the Goteborg randomised population-based prostate cancer
screening trial.
Lancet Oncol
2010;11(8):725-732.
10. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-
specific antigen in a community-based population of healthy
men: establishment of age-specific reference ranges
JAMA
1993;
270(7):860-864.
11. CatalonaWJ, SmithDS,Wolfert RLet al. Evaluation of percentage
of free serum prostate-specific antigen to improve specificity of
prostate cancer screening.
JAMA
1995;274(15);214-1220.
12. Rubens DJ, Gottlieb RH, Maldonado CE Jr, Frank IN. Clinical
evaluation of prostate biopsy parameters: gland volume and
elevated prostate-specific antigen level.
Radiology
1996;199(1):
159-163.
13. Rosenberg MT, Witt ES, Miner M, Barkin J. Apractical primary
care approach to lower urinary tract symptoms caused by benign
prostatic hyperplasia (BPH-LUTS).
Can J Urol
2014;21(Suppl 2):
12-24.
14. Schilling D, de Reijke T, Tombal B, de la TailleA, Hennenlotter J,
Stenzl A. The prostate cancer gene 3 assay: indications for use
in clinical practice.
BJU Int
2010;105(4):452-455.
15. Gomella LG. Circumcision: a spiritual medical or criminal act?
Can J Urol
2012;19(6):6530.
16. Mazzulli T. Diagnosis and management of simple and
complicated urinary tract infections (UTIs). Urology Update
for Primary Care Physicians.
Can J Urol
2012;19(Supp 1):42-48.
17. Gupta S, Loddh B, Singh AK et al. Comparing the efficacy of
tamsulosin and silodosin in the medical expulsion therapy for
ureteral calculi.
J Clin Diagn Res
2013;7(8):1672-1674.
18. Gomella LG, Petrylak DP, Shayegan B. Current management
of advanced and castration resistant prostate cancer.
Can J Urol
2014:21(Supp 1):1-6.
19. Greenspan M, Barkin J. Erectile dysfunction and testosterone
deficiency syndrome- the portal tomen’s health.
Can J Urol
2012;
19(Supp 1):18-27.
63
A guide to the management of urologic dilemmas for the primary care physician (PCP)
